← FDA ENFORCEMENT
D-0621-2024Class II
Glenmark Pharmaceuticals Inc., USA
What this record is not
A recall record is reproduced as FDA published it, and the classification is FDA’s. SPEQ adds no interpretation, and a recall concerns the products and dates in the record — it is not a statement about a company’s other products or its current status.
Recalling firm
Glenmark Pharmaceuticals Inc., USA
Product type
Drug
Status
Ongoing
Report date
2024-08-07
Distribution
U.S. Nationwide
Firm state
NJ
Product quantity
14,004 cartons
Initiated by
Voluntary: Firm initiated
SPEQ quality domain
Risk Management & CAPAReason for recall
CGMP Deviations
Product description
Glenmark, Azelaic Acid Gel, 15 %, 50 grams, Rx only, Manufactured by: Glenmark Pharmaceuticals Limited, Colvale-Bardez, Goa, 403513, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-626-52.
Code / lot info
Lot# 19241453; Exp MARCH 2026
Other recalls SPEQ maps to Risk Management & CAPA
2026-10-21Class IIHouston Rx LLC2026-10-21Class IICook Incorporated2026-10-21Class IIBaxter Healthcare Corporation2026-10-14Class IIQUANTUM OPS Inc
See all Risk Management & CAPA recalls →Data: U.S. FDA. Recall details are as reported by the FDA. The quality-domain mapping and severity are a SPEQ editorial interpretation of the recall reason, not an official FDA classification. Open the enforcement explorer →